Targeted treatment in the setting of hepcidin deficiency itself could represent an efficient way, as suggested by clinical observations obtained in hemochromatosis patients that have been transplanted for hepatocellular carcinoma [108]. This evidence concerns the gene HAMP and hemochromatosis type 1.